Mouse anti-Candida glabrata mannan hybridoma cell line and monoclonal antibody
By developing the mouse anti-Candida mannan hybridoma cell line and monoclonal antibody DC11, the problems of high infection rate and drug resistance of Candida gloss are solved, and efficient specific detection and diagnosis of Candida gloss are achieved, providing It is an important means of early treatment.
Patent Information
- Application Number
- CN202410993179.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-07-24
AI Technical Summary
Candida gloss has a high infection rate and strong drug resistance. It is difficult for the existing technology to achieve early diagnosis and effective treatment, especially in patients with HIV, tumors, and diabetes, and antifungal drug resistance leads to treatment failure.
The mouse anti-Castia glossy mannan hybridoma cell line DC11 and its monoclonal antibodies were developed. The Ig variable region gene was cloned by screening and RT-PCR method, and the antibody DC11 with high specificity and responsiveness was obtained for Detection of Candida glossy mannan.
Antibody DC11 reacts strongly with Candida gloss mannan and does not react with other Candida species and polysaccharides, providing efficient detection tools, ensuring specific recognition and diagnosis of Candida gloss, and laying the foundation for the anti-Candida gloss gene The basis of engineering antibodies.
Smart Images

Figure CN118515774B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of antibody preparation, and particularly relates to a mouse anti-Candida glabrata mannan hybridoma cell line and a monoclonal antibody. Background Art
[0002] Candida spp. Candida ) belongs to the phylum Ascomycota, also known as Candida, and is a common conditional pathogen. It causes disease by invading the host's mucous membranes and tissues, triggering local and systemic inflammatory responses. There are many species of Candida fungi, but only a few can cause disease in humans. Candida albicans is the most common and has the strongest pathogenicity, followed by Candida tropicalis, Candida glabrata, Candida krusei, and Candida parapsilosis.
[0003] Mannan often exists in the form of glycoprotein in a variety of microorganisms and is another important antigenic determinant on the surface of Candida besides glucan. Mannan is an important antigen in the body's inherent immunity and adaptive immunity and can induce a strong antibody response.
[0004] Candida glabrata is a conditional pathogen that colonizes mucosal surfaces and is widely found in nature. When the human immune function is reduced or the skin and mucosal environment changes, Candida glabrata can multiply in large numbers and cause infection of deep organs.
[0005] In recent years, with the increase in the number of patients with HIV, tumors, and diabetes, the infection rate of Candida glabrata has also increased year by year, and the aging population and invasive treatments will also increase the risk of infection. In invasive infections, Candida glabrata has become the second most common species of Candida albicans in some countries and regions, second only to Candida albicans. In addition, Candida glabrata is significantly resistant to antifungal drugs, which often leads to treatment failure. Due to its combination of pathogenicity and drug resistance, Candida glabrata infection presents a phenomenon of "high morbidity, high mortality, and high drug resistance", so early diagnosis and early treatment are particularly important. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a mouse anti-Candida glabrata mannan hybridoma cell line and a monoclonal antibody.
[0007] The technical solution adopted by the present invention is: a mouse anti-glabrata mannan hybridoma cell line, named DC11, classified as a hybridoma cell, with a preservation date of November 8, 2023, and the preservation unit is the General Microbiology Center of the China Microbiological Culture Collection Administration (CGMCC), and the preservation number is CGMCC No.45742.
[0008] Mouse anti-Candida glabrata mannan monoclonal antibody, antibody DC11 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises CDRH1 as shown in SEQ ID NO:1, CDRH2 as shown in SEQ ID NO:2, and CDRH3 as shown in SEQ ID NO:3, and the light chain variable region comprises CDRL1 as shown in SEQ ID NO:4, CDRL2 as shown in SEQ ID NO:5, and CDRL3 as shown in SEQ ID NO:6;
[0009] SEQ ID NO:1 SGIDFRRDWMS
[0010] SEQ ID NO:2 EVDPHSNRIKYTTSLKD
[0011] SEQ ID NO:3 PPYGARYFDV
[0012] SEQ ID NO:4 SASQDIGNYLN
[0013] SEQ ID NO:5 YTSSLHS
[0014] SEQ ID NO:6 QQYSQFPPYT
[0015] Preferably, the amino acid sequence of the heavy chain variable region of antibody DC11 is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:9;
[0016] Heavy chain variable region sequence
[0017] SEQ ID NO:7
[0018] GGLVQPGGSLKLSCAASGIDFRRDWMSWVRQTPGKGLEWIGEVDPPHSNRIKYTTSLKDKFIISRDNAKNTLYLQMIKVRSEDTGHYYCARPPYGARYFDVWGA GTTVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKK
[0019] Light chain variable region sequence
[0020] SEQ ID NO:9
[0021] MAPTQFLGLLLLCFQGTRCDIQMTQTTSSLSASLGDRVTISCSASQDIGNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDFSLTISNLEPEDIATYYCQQYSQFPPYTFGGGTKLEIKRADAAPTVS
[0022] Preferably, the antibody DC11 is produced by the mouse anti-Candida glabrata mannan hybridoma cell line with a deposit number of CGMCC No.45742;
[0023] A nucleic acid molecule comprising nucleotides encoding a mouse anti-Candida glabrata mannan monoclonal antibody.
[0024] Preferably, the nucleotide sequence of the heavy chain variable region of the antibody DC11 encoded by the nucleic acid molecule is as shown in SEQ ID NO:8, and the nucleotide sequence of the light chain variable region of the antibody DC11 encoded by the nucleic acid molecule is as shown in SEQ ID NO:10;
[0025] Heavy chain variable region nucleotide sequence
[0026] SEQ ID NO:8
[0027] GGTGGCCTGGTGCAGCCTGGAGGATCCCTGAAACTCTCCTGTGCAGCCTCAGGAATCGATTTTAGAAGAGACTGGATGAGTTGGGTCCGGCAGACTCCAGGGAAAGGGCTAGAATGGATTGGAGAAGTTGATCCACATAGCAATAGGATAAAATATACGACATCTCTAAAGGATAAATTCATCATCTCCAGAGACAACGCCAAAAATACGCTGTACCTGCAAATGATCAAAGTGAGATCTGAGGACACAGGCCATTATTACTGTGCAAGACCTCCGTACGGCGCCCGGTATTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCGCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGATCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCCCACCCGGCCAGCAGCACCAAGGTGGACAAGAAA
[0028] Nucleotide sequence of the light chain variable region
[0029] SEQ ID NO:10
[0030] ATGGCCCCTACTCAGTTTCTTGGTCTCCTGTTGCTCTGTTTTCAAGGTACCAGATGTGATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGTGCAAGTCAGGACATTGGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTAATCTAT TACACATCAAGTTTACACTCAGGCGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGACAGATTTTTCTCTCACCATCAGCAACCTGGAACCTGAAGATATTGCCACTTACTATTGTCAGCAGTATAGTCAGTTTCCTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAACGGGCTGATGCTGCACCAACTGTATCC
[0031] A kit for detecting mouse anti-Candida glabrata mannan comprises mouse anti-Candida glabrata mannan monoclonal antibody.
[0032] The advantages and positive effects of the present invention are as follows: providing a mouse anti-Candida glabrata mannan monoclonal antibody, which reacts strongly with Candida glabrata mannan, reacts weakly with Candida albicans mannan, does not react with Candida krusei mannan, Candida tropicalis mannan, and Candida parapsilosis mannan, and has no cross reaction with Cryptococcal capsular polysaccharide, 1,3-β-D glucan, Aspergillus galactomannan, lipopolysaccharide, and peptidoglycan. Based on these characteristics, a foundation is laid for the preparation of a genetic engineering antibody against Candida glabrata mannan. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 Protein electrophoresis of purified antibody DC11; 1. Marker, 2. DC11
[0034] Figure 2 Inclusivity assay results for antibody DC11;
[0035] Figure 3 Results of cross-reactivity assay of antibody DC11;
[0036] Figure 4 Results of antibody titer determination of antibody DC11;
[0037] Biological material: DC11, classified as hybridoma cell, the deposit date is November 8, 2023, the depository is the General Microbiology Center of China Microorganism Culture Collection Administration (CGMCC), and the deposit number is CGMCC No.45742. DETAILED DESCRIPTION
[0038] The following is a description of embodiments of the present invention.
[0039] The present invention relates to a mouse anti-glabrata mannan hybridoma cell line, wherein a biological material is named DC11, which belongs to a hybridoma cell, and its preservation number is CGMCC No.45742; the preservation place is the General Microbiology Center of China National Committee for the Preservation of Microorganisms; the address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing; the preservation date is November 8, 2023, and the detection is survival.
[0040] The present invention relates to a mouse anti-Candida glabrata mannan hybridoma cell strain. The hybridoma cell strain and its variable region sequence which stably secrete mouse anti-Candida glabrata mannan monoclonal antibody are obtained by screening mouse hybridoma monoclonal antibody and cloning Ig variable region gene by RT-PCR method. The antibody tolerance and specificity are identified by ELISA method, which lays a foundation for the research and development of anti-Candida glabrata mannan genetic engineering antibody.
[0041] The antibody DC11 produced by the mouse anti-Candida glabrata mannan hybridoma cell line is produced by the mouse anti-Candida glabrata mannan hybridoma cell line with a deposit number of CGMCC No. 45742; the antibody DC11 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises CDRH1 as shown in SEQ ID NO: 1, CDRH2 as shown in SEQ ID NO: 2 and CDRH3 as shown in SEQ ID NO: 3, and the light chain variable region comprises CDRL1 as shown in SEQ ID NO: 4, CDRL2 as shown in SEQ ID NO: 5 and CDRL3 as shown in SEQ ID NO: 6;
[0042] SEQ ID NO:1 SGIDFRRDWMS
[0043] SEQ ID NO:2 EVDPHSNRIKYTTSLKD
[0044] SEQ ID NO:3 PPYGARYFDV
[0045] SEQ ID NO:4 SASQDIGNYLN
[0046] SEQ ID NO:5 YTSSLHS
[0047] SEQ ID NO:6 QQYSQFPPYT
[0048] The amino acid sequence of the heavy chain variable region of antibody DC11 is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:9;
[0049] Heavy chain variable region sequence SEQ ID NO: 7
[0050] GGLVQPGGSLKLSCAASGIDFRRDWMSWVRQTPGKGLEWIGEVDPPHSNRIKYTTSLKDKFIISRDNAKNTLYLQMIKVRSEDTGHYYCARPPYGARYFDVWGA GTTVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKK
[0051] Light chain variable region sequence SEQ ID NO: 9
[0052] MAPTQFLGLLLLCFQGTRCDIQMTQTTSSLSASLGDRVTISCSASQDIGNYLNWYQQKPDGTVKLLIYYTSSLHSGVPSRFSGSGSGTDFSLTISNLEPEDIATYYCQQYSQFPPYTFGGGTKLEIKRADAAPTVS
[0053] The nucleotide sequence encoding the heavy chain variable region of antibody DC11 is shown in SEQ ID NO:8, and the nucleotide sequence encoding the light chain variable region of antibody DC11 is shown in SEQ ID NO:10;
[0054] Heavy chain variable region nucleotide sequence SEQ ID NO: 8
[0055] GGTGGCCTGGTGCAGCCTGGAGGATCCCTGAAACTCTCCTGTGCAGCCTCAGGAATCGATTTTAGAAGAGACTGGATGAGTTGGGTCCGGCAGACTCCAGGGAAAGGGCTAGAATGGATTGGAGAAGTTGATCCACATAGCAATAGGATAAAATATACGACATCTCTAAAGGATAAATTCATCATCTCCAGAGACAACGCCAAAAATACGCTGTACCTGCAAATGATCAAAGTGAGATCTGAGGACACAGGCCATTATTACTGTGCAAGACCTCCGTACGGCGCCCGGTATTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCGCAGCCAAAACGACACCCCCATCTGTCTATCCACTGGCCCCTGGATCTGCTGCCCAAACTAACTCCATGGTGACCCTGGGATGCCTGGTCAAGGGCTATTTCCCTGAGCCAGTGACAGTGACCTGGAACTCTGGATCCCTGTCCAGCGGTGTGCACACCTTCCCAGCTGTCCTGCAGTCTGACCTCTACACTCTGAGCAGCTCAGTGACTGTCCCCTCCAGCACCTGGCCCAGCGAGACCGTCACCTGCAACGTTGCCCACCCGGCCAGCAGCACCAAGGTGGACAAGAAA
[0056] Nucleotide sequence of the light chain variable region SEQ ID NO:10
[0057] ATGGCCCCTACTCAGTTTCTTGGTCTCCTGTTGCTCTGTTTTCAAGGTACCAGATGTGATATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGTGCAAGTCAGGACATTGGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTAATCTAT TACACATCAAGTTTACACTCAGGCGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGGACAGATTTTTCTCTCACCATCAGCAACCTGGAACCTGAAGATATTGCCACTTACTATTGTCAGCAGTATAGTCAGTTTCCTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAACGGGCTGATGCTGCACCAACTGTATCC
[0058] The mouse anti-Candida glabrata mannan monoclonal antibody produced by hybridoma cell DC11 reacts strongly with Candida glabrata mannan and can be used to detect Candida glabrata mannan. Through the study of antibody DC11, it was found that antibody DC11 reacts weakly with Candida albicans mannan, does not react with Candida krusei mannan, Candida tropicalis mannan, Candida parapsilosis mannan, and has no cross reaction with Cryptococcal capsular polysaccharide, 1,3-β-D glucan, Aspergillus galactomannan, lipopolysaccharide, and peptidoglycan. Based on these characteristics, this monoclonal antibody can be used for the detection of Candida glabrata mannan with better specificity.
[0059] The scheme of the present invention is further described below in conjunction with the accompanying drawings, wherein the experimental methods without specific operating steps are all carried out in accordance with the corresponding product instructions, and the instruments, reagents, and consumables used in the examples can all be purchased from commercial companies unless otherwise specified.
[0060] Example 1: Screening of mouse anti-Candida glabrata mannan hybridoma cell lines
[0061] Take 2mL of 3mg / mL Candida glabrata mannan. In an ice bath, slowly add 200uL of 100mg / mL CDAP. After 1min, add 0.1M TEA to adjust pH to 9.0, mix well, add 2mL 0.5M ADH (dissolved in 0.5M sodium bicarbonate), adjust pH to 8.0, react at 4℃ for 4h, and dialyze against 0.01M PBS 3500D for 24h. Add 500uL 10mg / mL bovine serum albumin and 20mg EDAC to the above solution to make the final concentration 0.02M, and react at 4℃ for 4h. Dialyze against 0.02M PBS 50kD overnight, and identify after centrifugation. Used for animal immunization.
[0062] The first immunization dose is 50ug / mouse, the adjuvant is Freund's complete adjuvant, subcutaneous multiple injection, and the interval between the second immunization is 2 weeks; the second immunization dose is 50ug / mouse, the adjuvant is Freund's incomplete adjuvant, intraperitoneal injection, and the interval between the third immunization is 2 weeks; the third and subsequent immunization doses, routes, and adjuvants are the same as the second immunization method, and the interval between the two immunizations is 2 weeks until the fourth immunization. Blood was collected from the tail vein of the mouse to determine the titer, and cell fusion was performed when the titer reached 1:8000 or above.
[0063] Immunize 50ug polysaccharide 3 days before fusion, without adjuvant. After blood was collected from the mouse eyeball, spleen cells of the successfully immunized mice were taken for cell fusion with myeloma SP2 / 0 cells (at a ratio of 10:1). During the fusion, 50% PEG was added to the spleen cells and myeloma cell clusters that were mixed and the supernatant was discarded in a 37°C water bath within 1 minute, and the mixture was shaken in a 37°C water bath for 1 minute, and then 20mL of serum-free 1640 medium was added within 5 minutes. Centrifuge at 1500rpm for 5 minutes, discard the supernatant, resuspend the cells with 1640 medium containing HAT, and pipette into a 96-well plate (2.5x10 7 Cells were cultured at 37°C and 5% CO2. The medium was half-changed on the third day after fusion and fully changed on the seventh day.
[0064] When the clones in the fusion plate are large enough, take 100μl of supernatant from each well for detection, and the method is the same as the titer detection method. The OD value of the negative well is more than twice that of the positive well, and the next cloning culture is carried out. The hybridoma clones that are screened positive are expanded from the 96-well plate to the 24-well plate for 3-5 days, and the culture supernatant is screened and tested again. The clones that are tested positive are then cultured for the next subclone, and the remaining cells are frozen. Collect the hybridoma cells in the 24-well plate, count the cells, and adjust the cell density to 10 / mL; spread the cells into the 96-well plate, 100μl per well, and culture in an incubator at 37°C and 5% CO2; after about 10 days of culture, clone formation can be seen, select the wells with only a single clone, aspirate the culture supernatant, and the detection method is the same as before. Select the positive clones and expand them to 24-well plates for culture. After the supernatant is tested again, select the positive clones for the second round of subclone culture. Generally, after multiple rounds of subclone culture, until all the test wells are positive, a stable hybridoma cell line is obtained. The positive hybridoma culture supernatant was selected and the antibody subtype was detected by using an antibody subtype detection kit. The monoclonal antibody in the present invention was numbered DC11, the heavy chain was a mouse IgG1 subtype, and the light chain was a κ chain.
[0065] Example 2: Preparation of mouse anti-Candida glabrata mannan monoclonal antibody
[0066] 2.1 Ascites preparation and purification
[0067] Hybridoma cells were washed with serum-free 1640 solution and 5x10 6 / 0.5mL / mouse was intraperitoneally injected into Balb / c mice pre-sensitized with liquid paraffin. After 7 to 10 days, the ascites was collected and the supernatant was collected at 10,000rpm for 5 minutes at 4 degrees. The antibodies in the ascites were crudely purified using the caprylic acid-ammonium sulfate method. The crudely purified antibodies were further purified using the AKTA protein purification system and 1mL Protein G purification pre-packed column according to the purification manual provided by GE. The results after purification are attached. Figure 1 .
[0068] 2.2 Determination of the inclusivity of the reaction with different Candida mannans
[0069] The indirect ELISA method was used to determine the tolerance of 5 types of Candida mannan. 1ug / mL of Candida albicans mannan, Candida glabrata mannan, Candida krusei mannan, Candida tropicalis mannan, and Candida parapsilosis mannan were coated, 100uL / well. 5% skim milk powder was used as the blocking solution. The antibody to be tested was first diluted to 1mg / mL and then diluted 1:1000 times as the primary antibody. The Abcam enzyme-labeled antibody was used as the secondary antibody at a dilution of 1:20000. After the reaction was completed, the absorbance was read at OD450nm. The uncoated group was set as the control. The OD value of the Candida mannan was more than 2.1 times that of the control group, indicating that the antibody reacted to this type of Candida mannan. The results are attached. Figure 2 Antibody DC11 reacts strongly with Candida glabrata mannan, weakly with Candida albicans mannan, and does not react with Candida krusei mannan, Candida tropicalis mannan, or Candida parapsilosis mannan.
[0070] 2.3 Determination of cross-reactivity with other polysaccharides
[0071] The cross-reactivity with other polysaccharides was determined by indirect ELISA. Cryptococcal capsular polysaccharide, 1,3-β-D glucan, Aspergillus galactomannan, lipopolysaccharide, and peptidoglycan were coated at 1ug / mL, 100uL / well. 5% skim milk powder was used as blocking solution. The antibody to be tested was first diluted to 1mg / mL and then diluted 1:1000 times as the primary antibody. Abcam enzyme-labeled antibody was used as the secondary antibody at a dilution of 1:20000. After the reaction, the absorbance was read at OD450nm. Results are shown in Figure 3 Antibody DC11 had no cross-reaction with other polysaccharides, indicating that the antibody had strong specificity.
[0072] 2.4 Monoclonal Antibody Titer Detection
[0073] The antibody titer was determined by indirect ELISA method. 1ug / ml of Candida glabrata mannan was coated, 100ul / well. 5% skim milk powder was used as blocking solution. The ascites was diluted from 1:1000, with a total of 12 dilutions. Abcam enzyme-labeled antibody was used as the secondary antibody after dilution of 1:20000. The OD was read at 450nm. At the same time, the uncoated group was set as a control. The OD value when the antibody was diluted 2048000 times was more than 2.1 times that of the control group, indicating that the ascites titer had reached 1:2048000. The results are attached Figure 4 The antibody DC11 prepared from ascites reacted with Candida glabrata mannan with a titer of up to 10 6 .
[0074] Example 3: Genetic verification of mouse anti-Candida glabrata mannan monoclonal antibody
[0075] Cloning of Ig variable region genes by RT-PCR
[0076] Total RNA extraction and single-stranded cDNA synthesis:
[0077] The total RNA of DC11 hybridoma cell line was extracted by Trizol method (kit purchased from Invitrogen), and the total RNA was reversed into cDNA library by M-mLV reverse transcriptase (purchased from Invitrogen).
[0078] Heavy chain backbone upstream primer
[0079] P1: 5'SAGGTGGMAGCTKCASSARTCWGG3' (SEQ ID NO:11)
[0080] Heavy chain variable region downstream primer
[0081] P2: 5' AGGCTTACTAGTACAATCCCTGGGCACAAT3' (SEQ ID NO: 12)
[0082] Light chain backbone region upstream primer
[0083] P3: 5'GACATTGTSATGACCCAGWCTCCA 3' (SEQ ID NO:13)
[0084] Light chain variable region downstream primer
[0085] P4: 5'GGATACAGTTGGTGCAGCATCAGCCCGTTT3' (SEQ ID NO:14)
[0086] Prepare PCR reaction system (50 μl) as follows:
[0087] cDNA: 2μl; upstream primer (10μM): 2μl; downstream primer (10μM): 2μl; dNTP mixture: 2μl; pfuDNA polymerase (5U / μl): 1μl; 10X pfu Buffer Ⅱ: 5μl; ddH2O: make up to 50μl.
[0088] Reaction conditions: pre-denaturation at 95°C for 5 min; repeat the following cycle 35 times: 95°C for 30 s, 58°C for 30 s, 72°C for 1 min; finally, extension at 72°C for 10 min.
[0089] Agarose gel electrophoresis was used to separate and recover the VL and VH fragments. The recovered VL and VH fragments were connected to the pMD19-T (simple) vector (Takara Company) respectively. The connection system is as follows:
[0090] 70 ng of VL PCR product / VH PCR product, 1 μl of pMD19-T (simple) vector, 5 μl of Solution I ligation reaction solution; add ddH2O to 10 μl, and ligate at 4°C overnight.
[0091] The ligation product was transformed into E. coli DH5α competent bacteria, cultured overnight at 37°C, and a single colony was picked. After shaking at 37°C for 2 hours, PCR identification of the bacterial solution was performed, and the cDNA of the corresponding antibody was used as a positive control. The reaction system (25 μl) was prepared as follows:
[0092] Bacterial solution: 1 μl, upstream primer (10 μM): 1 μl; downstream primer (10 μM): 1 μl; dNTP Mixture (2.5 μm each) 2 μl; Taq DNA polymerase (5U / μl): 0.5 μl; 10× Taq Buffer (Mg2+ plus): 2.5 μl; add water to 25 μl. The reaction conditions are the same as before.
[0093] The clones with positive PCR were selected for expansion culture, and the plasmids of positive clones were extracted with a plasmid extraction kit (Takara) and sent for sequencing. At least 5 clone samples of each chain of each antibody were sent for testing, and the sequencing results of at least three samples were the same. The heavy chain and light chain variable region sequences of antibody DC11 were successfully cloned and matched the characteristics of typical antibody variable region sequences after comparison.
[0094] The embodiments of the present invention are described in detail above, but the contents described are only preferred embodiments of the present invention and cannot be considered to limit the scope of implementation of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.
Claims
1. Mouse anti-Candida glabrata mannan hybridoma cell line, Features: It is named DC11, the deposit number is CGMCC No.45742, and the depository is the General Microbiology Center of China Culture Collection Administration.
2. Mouse anti-Candida glabrata mannan monoclonal antibody, Features: Antibody DC11 includes a heavy chain variable region and a light chain variable region, the heavy chain variable region includes CDRH1 as shown in SEQ ID NO:1, CDRH2 as shown in SEQ ID NO:2, and CDRH3 as shown in SEQ ID NO:3, and the light chain variable region includes CDRL1 as shown in SEQ ID NO:4, CDRL2 as shown in SEQ ID NO:5, and CDRL3 as shown in SEQ ID NO:
6.
3. The mouse anti-Candida glabrata mannan monoclonal antibody according to claim 2, Features: The amino acid sequence of the heavy chain variable region of antibody DC11 is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
9.
4. The mouse anti-Candida glabrata mannan monoclonal antibody according to claim 2 or 3, Features: Antibody DC11 is produced by the mouse anti-Candida glabrata mannan hybridoma cell line with the deposit number of CGMCC No.45742.
5. Nucleic acid molecules, Features: The invention comprises a polynucleotide encoding the mouse anti-Candida glabrata mannan monoclonal antibody according to claim 2 or 3.
6. The nucleic acid molecule according to claim 5, Features: The nucleotide sequence of the heavy chain variable region of the antibody DC11 encoded by the nucleic acid molecule is shown in SEQ ID NO:8, and the nucleotide sequence of the light chain variable region of the antibody DC11 encoded by the nucleic acid molecule is shown in SEQ ID NO:
10.
7. Kit for detecting Candida glabrata mannan, Features: The invention comprises the mouse anti-Candida glabrata mannan monoclonal antibody as described in any one of claims 2-4.
Citation Information
Patent Citations
Mouse anti-aspergillus galactomannan hybridoma cell strain, monoclonal antibody and application thereof
CN111925446A
Mouse anti-aspergillus galactomannan hybridoma cell strain, monoclonal antibody and application thereof
CN111925993A
Mouse anti-(1, 3)-beta-D glucan hybridoma cell strains, monoclonal antibodies and application
CN113249336A
Murine anti-talaromyces marneffei mannan protein hybridoma cell strain, monoclonal antibody and application
CN116769023A
